ABIVAX Société Anonyme Beheer

Beheer criteriumcontroles 1/4

De CEO ABIVAX Société Anonyme is Marc M. de Garidel, benoemd in May2023, heeft een ambtstermijn van 1.5 jaar. De totale jaarlijkse vergoeding van { bedraagt € 793.97K, bestaande uit 45.3% salaris en 54.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.06% van de aandelen van het bedrijf, ter waarde € 311.28K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.3 jaar en 3.3 jaar.

Belangrijke informatie

Marc M. de Garidel

Algemeen directeur

€794.0k

Totale compensatie

Percentage CEO-salaris	45.3%
Dienstverband CEO	1.5yrs
Eigendom CEO	0.06%
Management gemiddelde ambtstermijn	1.3yrs
Gemiddelde ambtstermijn bestuur	3.3yrs

Recente managementupdates

Recent updates

An Intrinsic Calculation For ABIVAX Société Anonyme (EPA:ABVX) Suggests It's 28% Undervalued

Dec 11

Is ABIVAX Société Anonyme (EPA:ABVX) Using Too Much Debt?

Jun 06

A Quick Analysis On ABIVAX Société Anonyme's (EPA:ABVX) CEO Salary

Dec 31

Analyse CEO-vergoeding

Hoe is Marc M. de Garidel's beloning veranderd ten opzichte van ABIVAX Société Anonyme's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-€177m
Mar 31 2024	n/a	n/a	-€163m
Dec 31 2023	€794k	€359k	-€148m

Compensatie versus markt: De totale vergoeding ($USD 831.82K ) Marc M. } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de French markt ($USD 551.93K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Marc M. te vergelijken met de prestaties van het bedrijf.

CEO

Marc M. de Garidel (66 yo)

1.5yrs

Tenure

€793,971

Compensatie

Mr. Marc M. P. de Garidel, M.B.A., serves as Director of Claris Biotherapeutics, Inc. He serves as CEO at ABIVAX Société Anonyme since May 5, 2023 amd serves as its Director. He had been its Interim Chair...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Marc M. de Garidel	CEO & Director	1.5yrs	€793.97k	0.060% € 311.3k
Philippe Pouletty	Founder & Director	no data	€35.00k	0.43% € 2.2m
Didier Blondel	EVP, CFO & Board Secretary	7.8yrs	geen gegevens	0.00059% € 3.0k
Didier Scherrer	Chief Scientific Officer	1.3yrs	geen gegevens	0.057% € 291.9k
Patrick Malloy	Senior Vice President of Investor Relations	1.3yrs	geen gegevens	geen gegevens
Ida Hatoum	Chief People & Compliance Officer	1.4yrs	geen gegevens	geen gegevens
Pierre Courteille	Chief Business Officer	no data	geen gegevens	0% € 0
Jerome Denis	Executive Vice President of Process Development & Manufacturing	1.2yrs	geen gegevens	geen gegevens
Ana Sharma	VP & Global Head of Quality	less than a year	geen gegevens	geen gegevens
Hema Keshava	Senior Vice President of Finance	no data	geen gegevens	geen gegevens
Chris Rabbat	VP & Global Head of Medical Affairs	no data	geen gegevens	geen gegevens
Kevin Shan	VP & Global Head of Biometrics	no data	geen gegevens	geen gegevens

1.3yrs

Gemiddelde duur

57.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ABVX wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Marc M. de Garidel	CEO & Director	1.5yrs	€793.97k	0.060% € 311.3k
Philippe Pouletty	Founder & Director	10.9yrs	€35.00k	0.43% € 2.2m
Sylvie Gregoire	Chair of the Board	less than a year	geen gegevens	geen gegevens
Christian Trepo	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Lawrence Stanberry	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Troy Ignelzi	Independent Director	1.3yrs	€44.33k	geen gegevens
Christoph Huber	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Claude Bertrand	Member of Scientific Advisory Board	5.1yrs	€4.94k	geen gegevens
Luc Teyton	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
June Lee	Independent Director	1.3yrs	€35.24k	geen gegevens
Corinna Bonsen-Thomas	Independent Non-Executive Director	7.4yrs	€135.16k	0% € 0
Ian McGowan	Chairman of Scientific Advisory Board	6.4yrs	geen gegevens	geen gegevens

3.3yrs

Gemiddelde duur

63.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ABVX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

ABIVAX Société Anonyme Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Abivax SA Announces Board Observer & Advisor Appointments

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax SA Appoints Patrick Malloy as Senior Vice President Investor Relations

ABIVAX Société Anonyme Announces Board Changes

Abivax Appoints Ida Hatoum as Chief People Officer

ABIVAX Société Anonyme, Annual General Meeting, May 05, 2023

Recent updates

ABIVAX Société Anonyme has filed a Follow-on Equity Offering in the amount of €150 million.

Abivax SA Announces Board Observer & Advisor Appointments

Abivax SA Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Abivax SA Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25Mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2- Years of Open-Label Maintenance

Does ABIVAX Société Anonyme (EPA:ABVX) Have A Healthy Balance Sheet?

Price target decreased by 18% to €29.18

Consensus revenue estimates increase by 18%

Consensus revenue estimates increase by 69%

Price target increased by 7.1% to €38.28

Abivax SA Provides Updates on Ongoing Clinical Trials

Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024

Is ABIVAX Société Anonyme (EPA:ABVX) A Risky Investment?

Consensus revenue estimates increase by 22%

New major risk - Revenue and earnings growth

Consensus revenue estimates decrease by 29%

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax Announces Update to Obefazimod Phase 2B Clinical Development Program in Moderately to Severely Active Crohn’s Disease

Abivax to Host KOL Investor Event to Review Phase 2B Clinical Data and Phase 3 Trial Design for Obefazimod in Patients with Moderately to Severely Active Ulcerative Colitis

New major risk - Share price stability

Price target decreased by 16% to €30.33

New minor risk - Share price stability

New major risk - Revenue and earnings growth

ABIVAX Société Anonyme has filed an IPO in the amount of $100 million.

New major risk - Revenue and earnings growth

Abivax SA Appoints Patrick Malloy as Senior Vice President Investor Relations

ABIVAX Société Anonyme Announces Board Changes

Abivax Appoints Ida Hatoum as Chief People Officer

No longer forecast to breakeven

Price target decreased by 16% to €41.25

ABIVAX Société Anonyme, Annual General Meeting, May 05, 2023

No longer forecast to breakeven

Abivax Receives FDA Agreement on Pediatric Development Plan with Obefazimod in IBD

Price target increased to €49.30

Insufficient new directors

Abivax Sa Announces First Us Patient Enrolled in Global Phase 3 Program with Obefazimod in Ulcerative Colitis

Price target increased to €49.30

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax Phase 3 Program with Obefazimod in Ulcerative Colitis Progresses with US IRB Approval

Price target decreased to €45.50

Price target decreased to €56.80

Is ABIVAX Société Anonyme (EPA:ABVX) Using Too Much Debt?

Forecast breakeven date moved forward to 2022

Insufficient new directors

Abivax Reports One-Year Efficacy and Safety Data of Abx464 Phase 2B Maintenance Trial in Ulcerative Colitis

Forecast breakeven date moved forward to 2022

Abivax SA Announces the Detailed Results of the Dose Escalation Phase of Its Clinical Phase 1/2 Study Conducted with ABX196

Forecast to breakeven in 2024

Consensus forecasts updated

Consensus forecasts updated

An Intrinsic Calculation For ABIVAX Société Anonyme (EPA:ABVX) Suggests It's 28% Undervalued

Abivax SA Receives FDA Feedback with Guidance on Advancing ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis

Price target increased to €63.56

No longer forecast to breakeven

Price target increased to €58.63

Abivax Reports Excellent Phase 2A Clinical Safety and Efficacy Results with 50Mg ABX464 in Rheumatoid Arthritis

Is ABIVAX Société Anonyme (EPA:ABVX) Using Too Much Debt?

ABIVAX Société Anonyme Reports Excellent Efficacy and Safety of ABX464 in Phase 2B Clinical Trial in Ulcerative Colitis and Plans to Proceed to Phase 3

Price target decreased to €35.95

New 90-day low: €21.00

Abivax Follows DSMB Recommendation to Stop the Phase 2B/3 Mir-Age Covid-19 Clinical Trial Due to Lack of Efficacy

Abivax Publishes Data of ABX464 Induction and Long-Term Maintenance Phase 2A Ulcerative Colitis Study in the Journal "Gastroenterology"

Abivax Appoints Sophie Biguenet as Chief Medical Officer

A Quick Analysis On ABIVAX Société Anonyme's (EPA:ABVX) CEO Salary

New 90-day high: €28.95

Price target raised to €38.97

Abivax Establishes Clinical, Regulatory and Manufacturing Framework for ABX464 Phase 3 Program and Potential Commercialization in 2021

ABIVAX Société Anonyme to Report First Half, 2021 Final Results on Sep 30, 2021

ABIVAX Société Anonyme to Report First Half, 2021 Results on Sep 23, 2021